+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hepatitis Therapeutics Market - Growth, Trends, and Forecasts (2023-2028)

  • PDF Icon


  • 115 Pages
  • April 2023
  • Region: Global
  • Mordor Intelligence
  • ID: 4987005
UP TO OFF until Mar 31st 2024
During the time frame of the forecast, the hepatitis therapeutics market is expected to grow at a CAGR of 3.5%.

The impact of COVID-19 on healthcare services had a substantial impact on the delivery of care and outcomes for patients with chronic diseases. Therefore, there was a decline in the treatment, diagnosis, and follow-up of patients with hepatitis B and C, which had a significant impact on the healthcare industry. Additionally, clinical trials of the drugs were reduced as more and more companies delayed the start of most new courses in several countries. In addition, the COVID-19 epidemic saw a decline in outpatient services for patients with chronic hepatitis, which also had a significant impact on overall market growth. The study published in July 2021 in PubMed stated that the COVID-19 pandemic affected hepatitis prevention, testing, treatment, and vaccination services globally. But the return of elective care procedures around the world is likely to bring the market's growth back to where it was before the pandemic.

The market is anticipated to witness rapid growth due to the growing incidence of hepatitis, growing government support for awareness of hepatitis diseases, and increased availability of highly technologically advanced medical products. Hepatitis is an inflammation of the liver. Hepatitis may be due to drugs, alcohol consumption, or other medical conditions affecting the liver. But in most cases, it is caused by a virus called viral hepatitis, and the most common types are hepatitis A, B, and C. Hepatitis B is very common and can lead to severe cirrhosis of the liver, which can be fatal. Moreover, government initiatives to increase awareness regarding hepatitis and its treatment are anticipated to boost market growth over the forecast period. For instance, in June 2022, the 'World Hepatitis Summit (WHS)' occurred as a virtual event. The World Hepatitis Summit 2022 was co-sponsored by the World Health Organization (WHO). The summit provides a platform for a broad hepatitis community to take stock of progress to date and share ideas, experiences, and best practises in addressing the many challenges of viral hepatitis.

Furthermore, according to the Hepatitis B Foundation 2022 update, two billion people have been infected with the hepatitis B virus (one out of three people). Approximately 1.5 million people become newly infected each year. Almost 300 million people are chronically infected. Thus, the increasing burden of hepatitis is propelling the growth of the market. Additionally, in March 2021, Dicerna Pharmaceuticals and Roche commenced the Phase II combination trial of the investigational GalXC RNAi candidate, RG6346, for the treatment of chronic hepatitis B virus (HBV) infection. In addition, in March 2022, VBI Vaccines Inc. received FDA approval for the 3-antigen HBV vaccine for adults in the United States, PreHevbrio for hepatitis B. Therefore, such research and development activities in the market are expected to drive market growth.

Therefore, the increase in the prevalence of the hepatitis B virus, the promising pipeline for hepatitis drugs, and government-sponsored programmes to encourage patients to accept hepatitis drugs are likely to drive the hepatitis therapeutics market over the forecast period. During the analysis period, the market is likely to grow slowly because of strict regulations and bad reimbursement policies.

Hepatitis Therapeutics Market Trends

Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market

Hepatitis C is a liver disease caused by the hepatitis C virus. Hepatitis C can range in severity from mild to fatal.Acute hepatitis C occurs within the first six months after exposure to the hepatitis C virus, and chronic hepatitis C can develop into lifelong hepatitis C if left untreated. According to data published by the World Health Organization (WHO) in July 2021, an estimated 58 million people have chronic hepatitis C virus, and about 1.5 million new infections occur annually. According to the same source, the hepatitis C virus is a blood-borne pathogen, and the most common form of infection is exposure to small amounts of blood. This often happens with unsafe injections and unsafe health care.

The hepatitis C segment is anticipated to witness growth in the hepatitis therapeutics market due to the rise in hepatitis infection globally. For instance, as per the ECDC 2022 report, 26 cases of hepatitis of unknown etiology were reported in May 2022 in Spain. Moreover, it is expected to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions, as well as the growing availability of effective drugs in the market. In addition, the introduction of several products by major players is expected to boost the segment's growth. For example, in June 2021, Gilead Sciences, Inc. received approval from the FDA for Epclusa (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C virus (HCV) in children under 3 years of age, regardless of the HCV genotype or severity of the liver disease. Furthermore, the rise in clinical studies related to hepatitis C is anticipated to drive market growth. For instance, in February 2022, the Task Force for Global Health sponsored a clinical trial to assess the outcomes of hepatitis C-affected mother-infant pairs exposed to direct-acting antivirals (DAAs) during pregnancy within a global clinical case registry.

Therefore, due to the rise in the prevalence of hepatitis and the increase in product launches and clinical studies associated with the treatment of hepatitis C, the segment is anticipated to witness growth in the market over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

Due to an increase in hepatitis infections and an increase in the commercial availability of hepatitis drugs in the region, North America is expected to hold a significant market share in the hepatitis therapeutics market. For example, between April and September 2022, PHAC looked into 28 cases of acute severe hepatitis in children in Canada that met the national case definition.

Moreover, the data published in the report Viral Hepatitis National Strategic Plan: 2021-2025 for the United States stated that the goal of the strategic plan is to improve viral hepatitis-related health outcomes of people with viral hepatitis, reduce viral hepatitis-related disparities and health inequities, and improve viral hepatitis surveillance and data usage, etc. In addition, favorable reimbursement policies, high rates of improved access to healthcare, and the availability of well-functioning healthcare infrastructure also stimulate growth across the regional market on a large scale.

Furthermore, the presence of key market players, coupled with growing awareness programmes and the introduction of the latest products in the region, is responsible for bolstering the market's growth in the United States. For instance, in December 2021, the United States Food and Drug Administration approved Pre Hebrio [a recombinant vaccine] to prevent infections caused by all known minor hepatitis B virus (HBV) infections in adults. However, a national strategic plan was launched by the United States Department of Health and Human Services in January 2021 to eradicate hepatitis. It included five main goals, objectives and strategies to achieve these goals, and indicators with measurable objectives for monitoring progress. Therefore, the introduction of such programmes by the government will improve the treatment of hepatitis in the country.

Thus, due to the rise in the prevalence of hepatitis, the increase in government initiatives and strategic plans for hepatitis, and the surge in product launches, it is anticipated that North America will witness growth in the market over the forecast period.

Hepatitis Therapeutics Market Competitor Analysis

The hepatitis therapeutics market is competitive and consists of several major players. However, in terms of market share, only a few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc., Gilead Sciences, Inc., AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited, and Cipla Inc.

Additional benefits of purchasing the report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Viral Hepatitis
4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
4.3 Market Restraints
4.3.1 Stringent Regulatory Issues
4.3.2 Poor Reimbursement Policies
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Disease Type
5.1.1 Hepatitis A
5.1.2 Hepatitis B
5.1.3 Hepatitis C
5.1.4 Hepatitis D
5.1.5 Other Types
5.2 By Drug Class
5.2.1 Interferon
5.2.2 Monoclonal Antibody
5.2.3 Non-structural protein 5A (NS5A) Inhibitors
5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
5.2.6 Multi Class Combination
5.2.7 Other Drug Classes
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Merck KGaA
6.1.2 Gilead Sciences Inc.
6.1.3 AbbVie Inc.
6.1.4 Bristol Myers Squibb Company
6.1.5 F Hoffmann-La Roche, Ltd
6.1.6 LAURUS Labs
6.1.7 Zydus Cadila
6.1.8 Hetero Healthcare Limited
6.1.9 NATCO Pharma Limited
6.1.10 Cipla Inc.
6.1.11 Johnson & Johnson
6.1.12 Biocon

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Merck KGaA
  • Gilead Sciences Inc.
  • AbbVie Inc.
  • Bristol Myers Squibb Company
  • F Hoffmann-La Roche, Ltd
  • LAURUS Labs
  • Zydus Cadila
  • Hetero Healthcare Limited
  • NATCO Pharma Limited
  • Cipla Inc.
  • Johnson & Johnson
  • Biocon